康方生物依沃西获批用于PD-L1阳性肺癌治疗
4月27日，康方生物（09926）发布公告，宣布其自主研发的双特异性抗体依达方®（依沃西，PD-1/VEGF）获得中国国家药品监督管理局（NMPA）批准，用于一线治疗PD-L1阳性非小细胞肺癌（NSCLC）。
这是依沃西获得的第二个适应症，标志着中国患者能够率先使用全球最优治疗方案。公告中提到，依沃西在临床研究中表现出显著的疗效，其与帕博利珠单抗的比较显示，中位无进展生存期（PFS）分别为11.14个月和5.82个月，依沃西组的疾病进展/死亡风险降低49%。
此外，在中期分析中，依沃西相较于帕博利珠单抗显著降低死亡风险22.3%。此次批准不仅为NSCLC的治疗提供了新的选择，也显示了依沃西的潜力，成为全球首个在头对头研究中获得显著阳性结果的药物。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10